To identify novel canonical NF-κB downstream factors that influence trametinib response, we built on results from our RNA-Seq screen by performing a focused RNAi-based screen of 45 genes, comparing RAP vs. RasG12V tumours. The gene discussed is NFKB1; the disease is neoplasm.